Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps ...
Good day, and welcome to the Invivyd REVOLUTION Program and Measles Update Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to turn the call over to ...
‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ was published in the Cochrane Database of Systematic Reviews at ...
I have been following the story here of the newest Alzheimers drugs, the first to show that they can actually slow the ...
Morning Overview on MSN
2-antibody RSV cocktail aims to block resistance as the virus evolves
Every winter, respiratory syncytial virus sends tens of thousands of U.S. infants to the hospital, filling pediatric ICU beds ...
Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory ...
New Alzheimer's drugs targeting brain amyloid show minimal real-world benefits, a major review found. While plaque reduction ...
A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum ...
A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum ...
Despite substantial progress in malaria control over the past two decades, malaria caused by Plasmodium falciparum remains a leading cause of morbidity and mortality in sub-Saharan Africa, ...
Alzheimer’s drugs which pharmaceutical firms hoped could revolutionise dementia treatment ‘likely have no clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results